[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digital-osteoarthritis-or-rheumatoid-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digital-osteoarthritis-or-rheumatoid-arthritis":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640857",false,"NCT07624994","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine","Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine: Phase II Clinical Study","CARSPECT II","Inclusion Criteria:\n\n* Karnofsky index \\> 70%\n* Obtaining written, signed and dated informed consent\n* Affiliation to a health insurance plan\n* For women of childbearing age (fertile, after menarche and until postmenopausal unless sterile after surgery) including on GnRH agonist for ovarian suppression: serum pregnancy test negative at baseline (within 7 days before injection of 99mTc-NTP 15-5). Menopause is defined as amenorrhea for at least 12 consecutive months with no other cause and FSH and oestradiol levels consistent with those of the post-menopausal period.\n* Ability and willingness to respect study visits, exams as well as protocol.\n\nRA Group:\n\n* certain diagnosis of rheumatoid arthritis less than 5 years old, according to the ACR\u002FEULAR criteria,\n* symptomatic (finger pain \\> 4 \u002F10 on a numerical scale),\n* active synovitis (clinical and ultrasound),\n\nGroup DOA:\n\n* certain diagnosis of symptomatic DOA less than 5 years old (finger pain \\> 4 \u002F10 on a numerical scale),\n* stopping NSAIDs for at least 8 days before the injection,\n\nExclusion Criteria:\n\n* Ongoing use of non-steroidal anti-inflammatory drugs,\n* Treatment by local joint corticoid infiltration at the hand level in the month preceding the administration of 99mTc-NTP 15-5,\n* History of osteoarticular hand surgery.\n* History of hand soft tissue surgery in the past 6 months\n* Patients or patients 18 years old,\n* Pregnant or breastfeeding patient,\n* IMC\\>30,\n* History of known allergy to excipients contained in the 99mTc-NTP 15-5 solution,\n* Persons deprived of their liberty, under guardianship\u002Fcuratorship, or safeguarding of justice,\n* Inability to submit to the medical follow-up of the trial for geographical, family, social or psychological reasons. These conditions must be discussed with the patient before registration in the study.\n\nRA Group:\n\n* Use of biotherapies (anti-TNF alpha, rituximab, abatacept, anti-IL6 and anti-JAK) as background treatment.\n* Patients with a history of hand DOA","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis",[26],"Digital Osteoarthritis or Rheumatoid Arthritis",[28,29],"proteoglycan tracer","cartilage","NOT_YET_RECRUITING","2026-06-03",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":20},"2026-06-01",{"date":38,"type":20},"2028-07-01",{"name":40,"class":41},"Centre Jean Perrin","OTHER",2,""]